53 completed, 9 terminated, 5 withdrawn, 4 active not recruiting. 32 Phase 1, 26 Phase 2, 13 Phase 3, 1 Phase 4.
Follow Medivation, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer ADT+Docetaxel+Enzalutamide - Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Active not recruiting | Wake Forest University Health Sciences | 40 | 2017-08-23 | 2026-07-29 |
| A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Talazoparib - Prostate Cancer | Phase 2 | Completed | Pfizer | 128 | 2017-07-04 | 2024-04-05 |
| An Open-Label Pharmacokinetics and Safety Study of Talazoparib Talazoparib - Advanced Solid Tumors | Phase 1 | Completed | Pfizer | 34 | 2017-02-21 | 2021-01-05 |
| Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) MDV9300 - Lymphoma, Large B-Cell, Diffuse, Primary Mediastinal Large B-cell Lymphoma | Phase 2 | Withdrawn | Medivation, Inc. | 2016-12-01 | 2016-11-25 | |
| Open-Label Extension and Safety Study of Talazoparib Talazoparib - Cancer | Phase 2 | Completed | Pfizer | 120 | 2016-11-08 | 2022-08-24 |
| A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors Talazoparib, Itraconazole, Rifampin - Advanced Solid Tumors | Phase 1 | Completed | Pfizer | 36 | 2016-11-07 | 2021-06-30 |
| A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors Talazoparib - Solid Tumor | Phase 1 | Completed | Pfizer | 38 | 2016-10-13 | 2019-12-17 |
| A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer Talazoparib, Temozolomide - Ovarian Cancer | Phase 2 | Withdrawn | Pfizer | 2016-10-01 | 2018-09-18 | |
| An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) Talazoparib - Advanced Solid Tumors | Phase 1 | Completed | Pfizer | 38 | 2016-09-30 | 2021-02-25 |
| Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer Enzalutamide, Placebo, Paclitaxel - Breast Cancer | Phase 3 | Withdrawn | Pfizer | 2016-09-01 | 2018-10-22 | |
| A Study of Talazoparib in Patients With Advanced Solid Tumors Talazoparib - Advanced Solid Tumors | Phase 1 | Completed | Pfizer | 6 | 2016-09-01 | 2018-12-17 |
| Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer Enzalutamide, Metformin Hydrochloride - Prostate Cancer | Phase 1 | Completed | University of California, Davis | 25 | 2016-06-22 | 2025-05-01 |
| Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer Enzalutamide, assessment - Breast Cancer, Early Stage | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 50 | 2016-05-19 | 2026-06-24 |
| A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment Enzalutamide - Metastatic Castration Resistant Prostate Cancer | Phase 4 | Terminated | Astellas Pharma Global Development, Inc. | 4 | 2015-10-28 | 2018-04-19 |
| European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) enzalutamide - Metastatic Castration Resistant Prostate Cancer | Completed | Astellas Pharma Europe Ltd. | 1763 | 2015-09-08 | 2024-10-21 | |
| Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy Enzalutamide, SRT - Adenocarcinoma of the Prostate | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 86 | 2015-03-28 | 2025-10-28 |
| A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer BMN 673 - Endometrial Cancer | Phase 2 | Withdrawn | University College, London | 2014-10-01 | 2021-08-06 | |
| Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate Enzalutamide, Abiraterone Acetate, Prednisone - Prostate Adenocarcinoma, Prostate Cancer | Phase 2 | Completed | Dana-Farber Cancer Institute | 75 | 2014-10-01 | 2022-04-19 |
| Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer degarelix, enzalutamide, trametinib - Prostate Cancer | Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 45 | 2014-09-23 | 2025-08-17 |
| PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors PARP inhibitor BMN-673, temozolomide, irinotecan hydrochloride - Metastatic Cancer, Unspecified Adult Solid Tumor | Phase 1 | Completed | Jonsson Comprehensive Cancer Center | 44 | 2014-06-12 | 2022-09-26 |
Showing 20 of 73. Sign in to see all of them.
Alzheimer Disease (19) · Prostatic Neoplasms (15) · Huntington Disease (13) · Breast Neoplasms (6) · Dementia (3) · Neoplasm Metastasis (3) · Neoplasms (3) · Leukemia, Myeloid, Acute (2) · Memory Disorders (2) · Neurodegenerative Diseases (2) · Carcinoma, Ovarian Epithelial (1) · Central Nervous System Diseases (1) · Cognitive Dysfunction (1) · Colorectal Neoplasms (1) · Delirium (1)
enzalutamide (29) · latrepirdine (24) · talazoparib (14) · Leuprolide (3) · Prednisone (3) · Abiraterone Acetate (2) · Dextromethorphan (2) · Itraconazole (2) · Omeprazole (2) · Radiotherapy (2) · Rifampin (2) · Temozolomide (2) · Warfarin (2) · pidilizumab (2) · Administration, Oral (1)
United States (51) · United Kingdom (12) · Germany (11) · Canada (8) · Belgium (7) · France (7) · Hungary (6) · Spain (6) · Italy (5) · Australia (4) · Moldova (4) · Poland (4) · Puerto Rico (4) · Russia (4) · Bulgaria (3)
Mary-Ellen Taplin, MD (2) · Andrew Armstrong, MD ScM FACP (1) · Christopher Logothetis, MD (1) · Daniel Song, M.D. (1) · Earle Burgess, MD (1) · Glenn Bubley, MD (1) · Jacalyn Rosenblatt, MD (1) · Karl D Kieburtz, MD (1)
PMID 25917876, PMID 25929560, PMID 18640457, PMID 20142523, PMID 23108692, PMID 24739897, PMID 25683285, PMID 25687533, PMID 25937426, PMID 27072954, PMID 30110579, PMID 30124753, PMID 30563931, PMID 30811282, PMID 31196032, PMID 31770456, PMID 32063492, PMID 33394722, PMID 33636278, PMID 33686631, PMID 34197212, PMID 34388386, PMID 34840720, PMID 35091441, PMID 35385726, PMID 36124924, PMID 36367998, PMID 36996380, PMID 37803017, PMID 39074346, PMID 39663356, PMID 41346252, PMID 42849324
2016 (6), 2009 (1), P30CA093373 (1), U10CA031946 (1)